Passa al contenuto
Merck
  • Associations among visual acuity and vision- and health-related quality of life among patients in the multicenter uveitis steroid treatment trial.

Associations among visual acuity and vision- and health-related quality of life among patients in the multicenter uveitis steroid treatment trial.

Investigative ophthalmology & visual science (2012-01-17)
Kevin D Frick, Lea T Drye, John H Kempen, James P Dunn, Gary N Holland, Paul Latkany, Narsing A Rao, H Nida Sen, Elizabeth A Sugar, Jennifer E Thorne, Robert C Wang, Janet T Holbrook
ABSTRACT

To evaluate the associations between visual acuity and self-reported visual function; visual acuity and health-related quality of life (QoL) metrics; a summary measure of self-reported visual function and health-related QoL; and individual domains of self-reported visual function and health-related QoL in patients with uveitis. Best-corrected visual acuity, vision-related functioning as assessed by the NEI VFQ-25, and health-related QoL as assessed by the SF-36 and EuroQoL EQ-5D questionnaires were obtained at enrollment in a clinical trial of uveitis treatments. Multivariate regression and Spearman correlations were used to evaluate associations between visual acuity, vision-related function, and health-related QoL. Among the 255 patients, median visual acuity in the better-seeing eyes was 20/25, the vision-related function score indicated impairment (median, 60), and health-related QoL scores were within the normal population range. Better visual acuity was predictive of higher visual function scores (P ≤ 0.001), a higher SF-36 physical component score, and a higher EQ-5D health utility score (P < 0.001). The vision-specific function score was predictive of all general health-related QoL (P < 0.001). The correlations between visual function score and general quality of life measures were moderate (ρ = 0.29-0.52). The vision-related function score correlated positively with visual acuity and moderately positively with general QoL measures. Cost-utility analyses relying on changes in generic healthy utility measures will be more likely to detect changes when there are clinically meaningful changes in vision-related function, rather than when there are only changes in visual acuity. (ClinicalTrials.gov number, NCT00132691.).

MATERIALI
N° Catalogo
Marchio
Descrizione del prodotto

Fluocinolone acetonide, European Pharmacopoeia (EP) Reference Standard
Supelco
Fluocinolone acetonide, analytical standard